Drug intelligence / Profile preview

IPP-203101

Development stage: Preclinical
Lead developer: ImmuPharma
Modality: Peptides, Small Molecules

Overview

IPP-203101 is a peptide-based experimental antibiotic developed by ImmuPharma for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) and other severe hospital-acquired infections. It is designed as a cationic peptide that carries an electrical charge and disrupts bacterial membranes, targeting the membrane potential of MRSA and related multidrug-resistant strains to reduce their ability to survive and develop resistance.[7][10][11] The program has been described as a novel anti-bacterial opportunity in preclinical development within ImmuPharma’s infectious disease pipeline.[3][5][10]

Beyond the preview

Go deeper on IPP-203101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IPP-203101.

Explore the full profile